Acetylsalicylic acid resistance and clinical outcome - The Hobikoglu study is worth noting

Canadian Journal of Cardiology

Volumn 23, Issue 3, 2007, Pages 207-208

  Buchanan, Michael R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; CANADA; CONSENSUS DEVELOPMENT; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; EDITORIAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RISK ASSESSMENT; THROMBOCYTE FUNCTION; ACUTE DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG RESISTANCE; NOTE; SYNDROME; TREATMENT OUTCOME;

ACUTE DISEASE; ASPIRIN; CORONARY ARTERIOSCLEROSIS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; SYNDROME; TREATMENT OUTCOME;

EID: 34247270204     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70745-6     Document Type: Editorial

References (10)

1. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5. (Erratum in 2006;48:1918).
2. Poston RS, Gu J, Brown JM, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;131:122-30.
3. Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6.
4. Zhang Y, Liang J, Zhou Y-J, Yuan H, Zhang Y-Z, Dong L. [Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi 2005;33:695-9.
5. Andersen K, Hurlen M, Arnesen H, Seljetflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37-42.
6. Yilmaz MB, Balbay Y, Caldir V, et al. Late saphenous vein graft occlusion in patients with coronary bypass: Possible role of aspirin resistance. Thromb Res 2005;115:25-9.
7. Grotemeyer K-H, Scharafinski H-W, Husstedt I-W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
8. Stejskal D, Proskova J, Lacnak B, et al. [Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications.] Vnitr Lek 2004;50:591-9.
9. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995;11:221-7.
10. Frelinger AL III, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation 2006;113:2888-96.